Mumbai, Feb. 23 -- The company stated that the supplies under the said mandate are expected to commence within the next 4-5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.

Morepen Labs further said that this engagement marks one of the most significant single CDMO mandates in the Company's history, as it scales its global manufacturing footprint.

Sushil Suri, chairman & managing director, said: "This mandate represents an important milestone in the evolution of Morepen's manufacturing platform.

We view CDMO as a natural extension of our established API strengths, creating additional avenues of scale, stability, and long-term value creation while con...